Cat# : THA-0008
Cat#: | THA-0008 |
Product Name: | Omalizumab |
Description: | Omalizumab is a monoclonal anti-immunoglobulin E (IgE) antibody used to treat asthma, chronic idiopathic urticaria, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergy. |
Sequences: | Not Available |
Molecular Weight: | 149000.0 Da (approximate) |
Introduction: | Omalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin E (IgE). IgE promotes the release of inflammatory mediators from mast cells and basophils during allergic and inflammatory reactions. By binding to IgE and neutralizing it, omalizumab reduces free IgE levels and prevents IgE from binding to its receptors on immune cells. Omalizumab was first approved in the US in 2003 and in Europe in 2005. It is used to treat a range of immune and inflammatory conditions, including allergies, urticaria, and asthma. |
Purity: | >99% by SDS-Page and HPLC analysis |
Formula: | Not Available |
Appearance: | Liquid |
For more information on how our products could help advance your project, please contact us.
ENTER YOUR EMAIL HERE TO SUBSCRIBE.
Copyright © 2024 Creative BioMart. All Rights Reserved.